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Background: Immunosuppressive and antiviral
prophylactic drugs are needed to prevent acute
rejection and infection after transplantation. We
assessed the efﬁcacy and safety of the introduc-
tion of universal valganciclovir prophylaxis in
combination with a tacrolimus/mycophenolate-
based regimen in kidney transplantation at our
centre.
Methods:We reviewed all consecutive patients
who underwent kidney transplantation over a 5.5-
year period. Patients transplanted from January
2000 to March 2003 (period 1) were compared to
patients from April 2003 to July 2005 (period 2).
In period 1 patients were treated with basiliximab,
cyclosporine, steroids and mycophenolate (or aza-
thioprine). Prophylaxis with valacyclovir was pre-
scribed in cytomegalovirus (CMV) D+/R- pa-
tients, while any R+ patients were managed with a
preemptive approach. In period 2, immunosup-
pression consisted of basiliximab or thymoglobu-
lin induction, tacrolimus, steroids and mycophe-
nolate. Three-month CMV prophylaxis with val-
ganciclovir was used in all at-risk patients.
Results: Data analysis included 73 patients
(period 1) and 70 (period 2). Acute rejection was
more frequent in period 1 than in period 2 (42%
vs 7%, p <0.001). Overall, 30% of patients in pe-
riod 1 were diagnosed with CMV infection/dis-
ease requiring antiviral treatment, compared with
11.4% in period 2 (p = 0.003). Late-onset CMV
disease remained a problem in D+/R- patients in
both periods. There was no difference in inci-
dence of BK virus nephropathy, fungal infections,
PTLD, graft loss or mortality. However, 4 cases
(5.7%) of delayed transient asymptomatic agranu-
locytosis were observed in period 2.
Conclusions: The present analysis indicates
that the combined regimen introduced in period
2 improved clinical results with a signiﬁcant de-
crease in acute rejection and in CMV infec-
tion/disease incidence. However, a unique syn-
drome of delayed transient agranulocytosis prob-
ably due to drug myelotoxicity was observed in a
subset of patients.
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MMF Mycophenolate mofetil
PCR Polymerase chain reaction
PTLD Post-transplant proliferative disorder
WBC White blood cells
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CMV Cytomegalovirus
CNI Calcineurin inhibitor
C4d Complement C4d fragment
D/R Donor/recipient
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Calcineurin inhibitors (CNI) remain the cor-
nerstone drugs of immunosuppressive regimens
after kidney transplantation. In a recent meta-
analysis, tacrolimus was associated with a lower
incidence of acute rejection than cyclosporine [1],
and recent trends indicate that tacrolimus/my-
cophenolate is currently the most frequently used
maintenance immunosuppressive regimen fol-
lowing kidney transplantation in the U.S. [2].
Cytomegalovirus (CMV) is the most impor-
tant viral pathogen after organ transplantation in
terms of morbidity and mortality [3, 4].Moreover,
CMV infection after organ transplantation has
been associated with “indirect effects” such as
acute rejection or predisposition to other infec-
tious diseases (i.e. fungal and bacterial infection)
[4, 5]. The type of immunosuppressive drug used
following transplantation has been involved in the
reactivation of CMV. For instance, one study in-
dicated that mycophenolate therapy may increase
the incidence of CMV infection [], while other
studies suggested that sirolimus may decrease the
risk of CMV infection after transplantation [7]. In
addition, antilymphocyte therapy (OKT3, or an-
tilymphocyte globulin) may reactivate CMV as a
result of potent immunosuppression and cytokine
release [3, 4].
Currently there are two main strategies for
prevention of CMV disease after organ transplan-
tation: antiviral prophylaxis and preemptive ther-
apy [3, 8–10]. Antiviral prophylaxis consists in ad-
ministration of an antiviral drug after transplanta-
tion, usually during a period of 3– months [8,
10]. Most transplant centres use antiviral prophy-
laxis only in high-risk patients (targeted prophy-
laxis), while other centres use it for all patients
(universal prophylaxis). Preemptive therapy con-
sists in monitoring for CMV appearance in blood
(e.g. with either CMV DNA PCR or antige-
naemia) and administering antiviral therapy only
when CMV viraemia is detected as a risk marker
for impending CMV disease []. Drugs which
have been used for prevention of CMV infection
are oral valacyclovir (approved only in kidney
transplant recipients) and intravenous and oral
ganciclovir. Recently, oral valganciclovir, a valyl-
ester prodrug of ganciclovir with an improved
bioavailability with respect to oral ganciclovir, has
been approved for CMV prophylaxis in kidney
and heart transplantation [10].
A recent meta-analysis showed that both
strategies (prophylaxis and preemptive) decreased
the incidence of CMV disease after organ trans-
plantation, but only antiviral prophylaxis seemed
to reduce bacterial infection, fungal infection and
also death [11]. However, the two strategies have
not been compared in large-scale prospective ran-
domised clinical trials.
At our transplantation centre we introduced
in April 2003 a new universal antiviral prophylaxis
regimen (a 3-month course of oral valganciclovir
in all at-risk patients) together with a new im-
munosuppressive strategy consisting in induction
therapy with basiliximab (or thymoglobulin in
immunologically high-risk patients) associated
with tacrolimus, mycophenolate and prednisone.
In this study we analyse the efﬁcacy and safety of
this new combined regimen and compare it with
the previous period (2000–2003).
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Patients and methods
We retrospectively analysed the clinical records and
electronic database of all consecutive patients undergoing
kidney transplantation at the Centre Hospitalier Univer-
sitaire Vaudois (University Hospital of Lausanne,
Switzerland) over a 5.5-year period (2000–2005) who
completed a follow-up of at least 12 months. Patients
transplanted from January 2000 to March 2003 (period 1)
were compared to patients transplanted from April 2003
to July 2005 (period 2).
Immunosuppressive regimen
In period 1, most patients (55/73, 7%) were treated
with basiliximab, 20 mg at day 0 and day 4, as induction
therapy. Maintenance therapy consisted in cyclosporine
(targeted plasma levels 150–200 mg/l), steroids (daily
bolus of 500 mg methylprednisolone on the ﬁrst 3 days
post-transplantation, followed by tapered steroids to a
dose of 5 mg prednisone per day at  months post-trans-
plantation) and mycophenolate mofetil (MMF) (initially
2 g per day) or azathioprine (1–2 mg/kg per day). Nine
patients (12%) received an immunosuppressive regimen
consisting of sirolimus (targeted plasma levels between 8–
12 mg/l), cyclosporine and steroids, without induction
therapy.
In period 2, induction therapy was basiliximab for de
novo kidney transplants (51/70, 73%). In the event of re-
transplant or if panel-reactive antibody was >50%, thy-
moglobulin at 1.5 mg/kg/day for 4 days was given. Main-
tenance therapy consisted in tacrolimus (targeted plasma
levels 8–10 mg/l), steroids (daily bolus of 500 mg, 250 mg,
and 125 mg methylprednisolone for the ﬁrst 3 days post-
transplantation, followed by tapered steroids to a dose of
5 mg prednisone per day at 3 months post-transplanta-
tion), and MMF (initially 2 grams per day). In hepatitis
C-infected patients, cyclosporine was given instead of
tacrolimus (4/70, %).
Antiviral prophylaxis
The CMV antibody status of donors and recipients
was determined by enzyme-linked ﬂuorescent assay for
CMV IgG (Vidas, Biomérieux, Marcy l’Etoile, France).
In period 1, antiviral prophylaxis with a high-dose
regimen (8 g per day, adapted to kidney function) of vala-
cyclovir was prescribed in CMV donor positive/recipient
Introduction
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negative (D+/R-) patients [12]. Otherwise a preemptive
antiviral approach based on intravenous ganciclovir was
used, as described [13]. Patients were monitored weekly
for  weeks and then biweekly for another month and a
half after organ transplantation (preemptive strategy) or
after cessation of valacyclovir prophylaxis (monitoring),
for a 3-month period. In patients receiving sirolimus,
prophylaxis with cotrimoxazole (1 single-strength cap-
sule per day) was given for  months to prevent Pneumo-
cystis infection.
In period 2, 3-month universal CMV prophylaxis
with 450 mg per day of valganciclovir was given starting
on postoperative day 3, except in D-/R- patients, for
whom valacyclovir (1 g per day) was used (for herpes pro-
phylaxis). Patients were thereafter monitored by CMV
blood culture (until April 2004), or by CMV DNA PCR
[13], every 15 days for 3 months after cessation of valgan-
ciclovir prophylaxis. Cotrimoxazole (1 single-strength
capsule per day) was given to all patients for  months to
prevent Pneumocystis infection. In the event of allergy,
cotrimoxazole was replaced by atovaquone and levo-
ﬂoxacin.
Deﬁnitions and management of CMV infection
The deﬁnition of infectious diseases, including
CMV infection and disease, appearing after transplanta-
tion followed the recently published American Society of
Transplantation recommendations for screening, moni-
toring and reporting of infectious complications in im-
munosuppression trials in recipients of organ transplan-
tation [14]. Brieﬂy, CMV active infection was deﬁned by
the detection of CMV in blood or in appropriate speci-
mens, and CMV disease was deﬁned by the evidence of
CMV infection with attributable symptoms. CMV dis-
ease was classiﬁed as tissue-invasive disease, if there was
evidence of localised CMV infection in a biopsy or an-
other appropriate specimen, or as CMV syndrome if
there was no such evidence [14]. Since two techniques
with different sensitivity measuring CMV on blood were
used during the study period, in order to avoid selection
bias we separately analysed patients with high-level vi-
raemia or DNAaemia deemed to require antiviral ther-
apy and patients with “low-grade viraemia” (a positive
test for CMV DNA with levels below 10.000 copies/10
cells or a blood culture with fewer than 10 infectious
units / 10 WBC).
Treatment with intravenous ganciclovir (5 mg/kg
bid, adapted to renal function) was started for 2 or 3
weeks, if patients developed signiﬁcant CMV infection
(CMV disease and/or high-level viraemia) [13, 15]. After
stopping ganciclovir administration, CMV DNA was
monitored in whole blood by real time PCR every two
weeks for three additional months. Since November
2002, in the context of a pilot study, intravenous ganci-
clovir was replaced by oral valganciclovir (00 mg bid,
adapted to renal function) to treat recipients with CMV
infection or disease. Our experience in the treatment of
CMV with valganciclovir has been published previously
[1].
Deﬁnitions and management of rejection
In cases of acute renal dysfunction renal biopsy was
performed. Acute rejection was deﬁned by the Banff 7
working classiﬁcation of renal allograft pathology [17].
Since 2003, C4d staining has been performed on all renal
allograft biopsies and correlated with the presence of
donor-speciﬁc antibody in recipient’s serum.
Treatment for acute rejection consisted of 3 days of
high-dose methylprednisolone (500 mg daily boluses),
followed by a prednisone taper. Additionally, steroid-re-
sistant cases were treated with antilymphocyte globulin
for 4–7 days.
Statistical analysis
Discrete variables were compared using a c2 or a
Fischer exact test. Continuous variables were compared
using a Student’s or a Mann-Whitney’s test. All analyses
were performed using STATA software (Intercooled
STATA 8.2) and a p value <0.05 was considered to be sta-
tistically signiﬁcant.
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Results
Patients
Seventy-six patients were transplanted in pe-
riod 1. Three patients received a double trans-
plantation (2 liver and kidney, and 1 heart and kid-
ney) and were excluded from the present analysis.
Thus 73 kidney transplantations were included in
period 1. 70 patients were transplanted in period
2. Baseline clinical characteristics of both groups
are shown inTable 1, and were comparable.There
was a trend towards more advanced age in period
1 compared to period 2, but it did not reach statis-
tical signiﬁcance.
In period 2, one patient developed renal ar-
tery thrombosis at day 1 post-transplantation (pri-
mary non-function) and returned to dialysis, and
one patient received a non-functional graft that
was explanted on the day of transplantation.Thus,
in period 2, 7% of patients had a functioning
graft after a year’s follow-up, compared to 8% of
patients in period 1 (p = 0.0). As shown in Table
2, median serum creatinine 12 months after trans-
plantation was 15 mmol/l in period 1 compared
to 137 mmol/l in period 2 (p = 0.10).
After a year of follow-up there were no deaths
in period 2. In period 1 a 0-year-old patient died
of Pneumocystis jirovecii pneumonia 7 months after
transplantation; a 50-year-old patient died of car-
diorespiratory arrest 1 month after transplanta-
tion, and a 1-year-old patient died of probable
invasive aspergillosis 1 days after transplantation.
This latter patient had concomitant active CMV
infection at the time of death.
Acute rejection
Acute rejection was more frequent in period 1
than in period 2 (42% of patients vs 7% respec-
tively, p <0.001). In period 1 there were 38
episodes of acute rejection in 31 patients. 27 acute
rejection episodes were treated only with boluses
of methylprednisolone. Eleven episodes were ad-
ditionally treated with antilymphocyte therapy. In
period 2 ﬁve patients had episodes of acute rejec-
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tion: three episodes of cellular rejection were
treated with boluses of methylprednisolone only;
one episode of acute humoral rejection was
treated with boluses of methylprednisolone,
OKT3, intravenous immunoglobulin and plasma-
pheresis; and one episode of acute rejection re-
quired both boluses of methylprednisolone and
antilymphocyte therapy.
CMV infection
The results concerning CMV infection are
shown in Table 3. In period 1, 14 patients were
D-/R-. Of the remaining 5 patients, 31 had pos-
itive blood cultures for CMV. Nine episodes were
identiﬁed (per deﬁnition) as low-grade viraemia,
and thus a total of 22 patients with high-grade vi-
raemia were treated with ganciclovir. Six patients
had CMV disease (ﬁve patients had CMV syn-
drome and one patient CMV colitis). All  pa-
tients were D+/R- and four patients had received
antiviral prophylaxis with valacyclovir before
CMV disease. Sixteen patients had asymptomatic
active CMV infection. Of these, 4 had previously
received antiviral prophylaxis.Treatment of CMV
disease consisted of 2–3 weeks’ intravenous ganci-
clovir. One patient died of probable disseminated
aspergillosis 3 days after starting intravenous gan-
ciclovir. He had asymptomatic active CMV infec-
tion but with high-grade viraemia. It was notable
that, at the end of period 1 (November 2002 –
March 2003), oral valganciclovir was used in 5 pa-
tients to treat their active CMV infection (3 with
asymptomatic infection and 2 with CMV syn-
drome). Overall, the mean duration of antiviral
therapy was 2 ± 12 days. A total of 12 patients
out of 22 (54%) had a relapse of asymptomatic ac-
tive CMV infection, and 4 patients required a sec-
ond course of antiviral therapy.
In period 2, 11 patients were D-/R-. Of the
remaining 5 patients, 25 had either positive
CMV blood culture or detectable CMV DNA
after stopping valganciclovir prophylaxis. Seven-
teen episodes were identiﬁed (per deﬁnition) as
low-grade viraemia. Eight patients (11%) were
diagnosed with CMV disease, of whom 7 had
CMV syndrome and one probable tissue-invasive
disease (acute hepatitis). A point to note was that 3
patients out of the seven with CMV syndrome
had diarrhoea, which improved after administra-
tion of valganciclovir therapy. Most patients
(75%) with CMV disease in period 2 were D+/R-.
All patients were treated with oral valganciclovir
72Valganciclovir prophylaxis in kidney transplantation
Period 1 Period 2
Jan 00-Mar 03 Apr 03-Jul 05 p value
Number of patients 73 70
Mean age 48 ± 13 44 ± 14 0.0
Male sex 47 (4%) 50 (71%) 0.37
White race 71 (7%) 7 (%) 0.7
No. of HLA-antigen mismatches 4.0 ± 1.0 3.8 ± 1. 0.
PRA >50% 2 (3%) 3 (4%) 1.0
Previous renal transplantation-no. (%) 12 (1%) 14 (20%) 0.7
CMV serostatus pattern
D+/R- 13 (18%) 1 (23%)
D+/R+ 27 (37%) 31 (44%)
0.4
D-/R+ 1 (2%) 12 (17%)
D-/R- 14 (1%) 11 (1%)
Antiviral prophylactic strategy
Valacyclovir (anti-CMV) 7 (10%) 0 (0%)
Valacyclovir (anti-HSV) 0 (0%)  (13%)
<0.001
Valganciclovir 1 (1%) 1 (87%)
None 5 (8) 0 (0)
Induction therapy
Anti-IL2-receptor 55 (7%) 51 (73%)
Anti-thymocyte globulin 8 (11%) 1 (27%) 0.001
None  (12%) 0 (0%)
Maintenance immunosuppression
Prednisone 72 (%) 70 (100%)
Cyclosporin A 57 (7%) 4 (%)
Tacrolimus 15 (21%)  (4%) <0.001
Sirolimus  (12%) 0 (0%)
Mycophenolate 41 (57%) 70 (100%)
Azathioprine 5 (7%) 0 (0%)
CMV: cytomegalovirus, D: donor, HSV: herpes simplex virus, PRA: panel-reactive antibody, R: recipient
Table 1
Clinical characteris-
tics of patients.
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for a mean duration of 44 ± 32 days. Only two
cases of asymptomatic CMV viraemia relapse
were observed after the end of valganciclovir
therapy and resolved without antiviral therapy. It
was noteworthy that 2 patients developed adverse
events during valganciclovir treatment: one case
of thrombocytopenia and one case of pancytope-
nia which resolved after discontinuation of val-
ganciclovir.
Agranulocytosis during universal
valganciclovir prophylaxis
Four cases (5.7%) of agranulocytosis (ab-
solute neutrophil count <500 cells/mm3) occur-
ring during the ﬁrst three months after transplan-
tation were observed in period 2.The agranulocy-
tosis was delayed and transient, i.e. it occurred
abruptly 74 ± 20 days after transplantation, was
asymptomatic and recovered within 3–7 days after
discontinuation (or interruption) of MMF and
valganciclovir. G-CSF was safely administered to
2 out of 4 patients to help reverse the neutrope-
nia. No patient was found to have CMV infection
or any other viral or bacterial infection (which
might have played an aetiological role) at the time
of the agranulocytosis episode and, importantly,
there were no cases of agranulocytosis-associated
sepsis. No signiﬁcant association with prior thy-
moglobulin administration (during induction im-
munosuppression) was found. In 2/4 patients,
MMF could be successfully resumed (but at a
lower dosage) without any subsequent problem or
neutropenia relapse.Valganciclovir was discontin-
ued prematurely in 3/4 patients, and was resumed
in 1/4 patient to complete the drug prophylaxis
course. A point to note was that none of the 3 pa-
tients with premature dicontinuation of valganci-
clovir had CMV reactivation in the ensuing weeks
or months.
BK virus nephropathy, PTLD and fungal
infection
There were no differences between the two
periods in terms of incidence of BK virus
nephropathy (4% vs. 4%) or post-transplant lym-
phoproliferative disease (0% vs. 1%). As men-
tioned above and in Table 2, a single case of prob-
able invasive aspergillosis was diagnosed.
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Period 1 Period 2
Jan 00-Mar 03 Apr 03-Jul 05 p value
Number of patients 73 70
Patients with acute rejection 31 (42%) 5 (7%) <0.001
Total episodes of acute rejection 38 5
Median creatinine (mmol/dl) 15 137 0.10
Agranulocytosis episodes* 0 (0%) 4 (5.7%) 0.055
BK virus nephropathy** 3 (4%) 3 (4%) 1.0
PTLD** 0 (0%) 1 (1%) 1.0
Invasive fungal infection 1 (1%) 0 (0%) 1.
Graft loss 8 (11%) 2 (3%) 0.0
Death 3 (4%) 0 (0%) 0.24
* Agranulocytosis: <500 neutrophils per ml
** All cases of BK virus nephropathy and PTLD were biopsy-proven
PTLD: post-transplant lymphoproliferative disorder
Table 2
Patient outcome after
12-month follow-up.
Period 1 Period 2
Jan 00-Mar 03 Apr 03-Jul 05 p value
Number of patients 73 70
CMV active infection or disease requiring therapy* 22 (30%) 8 (11%) 0.007
D+/R- /22 (41%) /8 (75%) 0.2
CMV asymptomatic infection 1 (22%) 0 (0%) <0.001
Time from transplantation to ﬁrst CMV viraemia detection, days 44 (27-128) –
CMV disease  (8%) 8 (11%) 0.
Syndrome 5 (7%) 7 (10%)
Tissue-invasive disease 1 (1%) 1 (1%)
Time from transplantation to CMV disease diagnosis, days 118 (33-213) 13 (108-171) 0.3
Duration of antiviral therapy 2 ± 12 44 ± 32 0.015
Relapse episodes after stopping therapy 12 2 0.22
* Signiﬁcant CMV active infection/disease requiring therapy (CMV disease and/or CMV PCR positive >10.000 copies/10 cells
or ≥10 infectious units /10 WBC by blood culture)
Table 3
Incidence of CMV in-
fection at 12 months
after organ transplan-
tation.
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In the present study we analysed the effect of
introducing universal anti-CMV valganciclovir
prophylaxis in conjunction with a tacrolimus/
MMF-based maintenance immunosuppressive
regimen in kidney transplant recipients. Despite
the higher net state of immunosuppresion in the
second period, the incidence of CMV infection
requiring treatment was signiﬁcantly reduced
from 30 to 11%. This reduction was due to a sig-
niﬁcant decrease in the incidence of asympto-
matic CMV infection associated with valganci-
clovir use in period 2, while the incidence of
CMV disease was not signiﬁcantly reduced.
There are some advantages of the universal
prophylaxis approach with respect to the preemp-
tive approach. First, it is simpler. During the ﬁrst
three months after transplantation, valganciclovir
very effectively inhibits CMV replication and
prevents the appearance of CMV infection during
the time of most intense immunosuppression. In
contrast, the preemptive approach is relatively
complex and in our experience more difﬁcult to
implement. We have previously shown that mor-
bidity due to CMV infection depends on compli-
ance with preemptive approach guidelines [15].
However, it has been argued that by exposing re-
cipients to some low-level viral replication, the
preemptive approach may be somewhat beneﬁcial
and lead to an earlier anti-CMV immune re-
sponse (compared to the prophylactic approach),
i.e. it may reduce the risk of late CMV disease
[18]. Here it should be emphasised that there are
as yet no data regarding late CMV disease in
large, prospective, comparative studies of these
two (prophylactic vs. preemptive) approaches [1,
20]. At our centre we previously identiﬁed a pat-
tern of deleterious protracted infection with re-
current episodes of high level CMV viraemia by
using the preemptive approach [13]. The major
predictor of protracted CMV infection was the
same as for late disease, namely the high-risk
(D+/R-) CMV serostatus pattern.
The advantages of universal prophylaxis for
all at-risk patients may be the reduction of both
the “direct” and “indirect effects” of CMV infec-
tion [4], in particular a decrease in acute rejection
and a reduction in other infectious complications.
In our study the reduction in the incidence of
acute allograft rejection in period 2 was probably
mainly due to the switch toward a more potent
and efﬁcacious immunosuppressive regimen.
Whether valganciclovir prophylaxis, as an inde-
pendent parameter, may also have helped to re-
duce the incidence of acute rejection (e.g. by
suppressing asymptomatic CMV viraemia) can-
not be demonstrated in the present study due to
its retrospective, non-randomised nature.
However, there are some drawbacks to uni-
versal prophylaxis, such as late-onset CMV dis-
ease or increased exposure to an anti-CMV drug
which has potential side-effects. Late-onset CMV
disease in D+/R- recipients remains a signiﬁcant
problem, and CMV disease appearing after dis-
continuation of antiviral prophylaxis is indeed in-
creasingly described in the literature [10, 18, 21].
Thus, monitoring for CMV infection after dis-
continuing prophylaxis is mandatory, particularly
in D+/R- recipients. Late-onset CMV disease is
often characterised by tissue-invasive CMV dis-
ease, especially colitis or hepatitis. Although it has
been reported that the clinical manifestations of
late-onset CMV disease are more severe [22], in
our series this was not so since all cases responded
well to anti-CMV therapy without sequelae.
Second, even if valganciclovir is generally
well tolerated, toxicity may still be a concern. In
this regard it seems important to emphasise the
description in this series of 4 cases (5.7%) of
abrupt agranulocytosis in period 2, i.e. when they
were receiving both valganciclovir and MMF. All
cases were reversible without complications after
drug discontinuation (or interruption), but this
adverse event does raise the question of establish-
ing the minimally effective valganciclovir prophy-
lactic dose for each individual recipient. We sug-
gest that this unique clinical ﬁnding of “delayed
asymptomatic agranulocytosis” in 5.7% of kidney
transplant recipients receiving two potentially
myelotoxic drugs should be monitored closely
(and reported) as an additional endpoint in future
clinical studies using valganciclovir prophylaxis.
The precise explanation for the delayed nature of
the severe neutropenia was not determined. A
possible mechanism may be the previously docu-
mented progressive increase in the bioavailability
of MMF during the ﬁrst three months after
transplantation, interacting with concomitantly
administered valganciclovir and resulting in
myelotoxicity [23]. With the exception of this
haematological adverse event, valganciclovir was
well tolerated and very user-friendly.
In period 2 a ﬁxed dose of 450 mg per day of
valganciclovir was administered regardless of al-
lograft function. On average, kidney allograft
function was good or excellent (median serum
creatinine at one month of 130 mol/l, estimated
glomerular ﬁltration rates [GFRs] ranging from
50 to 70 ml/min). We did not identify break-
through CMV disease during prophylaxis but we
cannot exclude some low-level asymptomatic
CMV viraemia since CMV surveillance by PCR
was performed only after discontinuation of
prophylaxis. It is noteworthy that all patients who
developed CMV disease after discontinuation of
antiviral prophylaxis received oral valganciclovir
again and responded well to the second course of
antiviral therapy.Thus we encountered no clinical
suspicion of the emergence of ganciclovir-resis-
tant CMV strains. Prospective randomised trials
are also needed to determine the optimal dose (ef-
74Valganciclovir prophylaxis in kidney transplantation
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ﬁcacious and safe) and duration of valganciclovir
for CMV prophylaxis after kidney transplantation
[24, 25]. In particular, valganciclovir pharmacoki-
netic analysis should be performed for GFRs of
around 0 ml/min or higher, in order to validate
(or not) the dose of 450 mg/day we now routinely
use in our centre.
There are some limitations to the current
analysis. Because of the retrospective nature of
the study, tissue-invasive CMV disease may be
underdiagnosed due to incomplete clinical infor-
mation. For example, some patients with CMV
syndrome and diarrhoea were not diagnosed as
having “tissue-invasive disease” because
colonoscopy with biopsies was not performed in
all cases. In addition, two different methods of de-
tecting CMV were used during the 5.5-year study
period, quantitative PCR showing higher sensi-
tivity than blood culture. Because CMV infection
may carry a risk of being over-diagnosed in period
2 (because of the more sensitive PCR technique),
we decided to deﬁne and use a comparable end-
point, i.e. signiﬁcant CMV active infection or dis-
ease requiring treatment.
In conclusion, our analysis showed that val-
ganciclovir prophylaxis during period 2 was very
effective in reducing the incidence of CMV infec-
tion requiring therapy in a cohort of patients re-
ceiving a maintenance immunosuppressive regi-
men of tacrolimus/mycophenolate. The protocol
used in period 2 led to a signiﬁcantly improved
outcome both in terms of acute rejection and of
CMV infection/disease, thus achieving the goal of
an integrated immunosuppressive and antimicro-
bial approach which as been referred as “the ther-
apeutic prescription” by R. Rubin [2]. However,
we did not observe a decrease in late-onset CMV
disease after discontinuation of valganciclovir
prophylaxis in D+/R- patients. Occurrence of
late-onset CMV disease was not associated with
severe morbidity or mortality. Surveillance with
PCR for CMV and a low clinical diagnostic
threshold are probably necessary after discontinu-
ation of valganciclovir prophylaxis in D+/R- pa-
tients. Finally, our ﬁndings emphasise that special
attention to new and unexpected clinical events,
such as “delayed transient agranulocytosis”, is
mandatory in the current era of the more effective
but also more powerful drugs that are used in
transplant recipients.
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